What is the significance of a fasting C‑peptide of 0.94 ng/mL and how should it guide diabetes evaluation and management?

Fasting C-Peptide of 0.94 ng/mL: Clinical Significance

A fasting C-peptide of 0.94 ng/mL (approximately 0.31 nmol/L or 310 pmol/L) falls into the indeterminate range and suggests either type 1 diabetes, LADA, or MODY rather than typical type 2 diabetes, requiring further evaluation with autoantibody testing and clinical context to guide appropriate insulin therapy decisions.

Interpretation Based on Current Guidelines

According to the 2025 ADA Standards of Care, your C-peptide value of 0.94 ng/mL (approximately 310 pmol/L) falls into the 200-600 pmol/L range, which is classified as "indeterminate" 1. This range is typically consistent with:

• Type 1 diabetes (most likely)
• LADA (latent autoimmune diabetes in adults)
• MODY (maturity-onset diabetes of the young)
• Long-standing type 2 diabetes with significant beta-cell failure (particularly in patients with normal/low BMI)

Algorithmic Approach to Classification

Step 1: Assess Clinical Features

Features suggesting Type 1/LADA:

• Age <35 years at diagnosis
• BMI <25 kg/m²
• Presence of weight loss
• History of ketoacidosis
• Absence of metabolic syndrome features
• Family history of autoimmunity

Features suggesting Type 2:

• BMI ≥25 kg/m²
• No weight loss
• No ketoacidosis history
• Longer duration with milder symptoms before diagnosis
• Features of metabolic syndrome

Step 2: Order Autoantibody Testing

The guideline explicitly recommends measuring GAD antibodies first, followed by IA-2 and/or ZnT8 if GAD is negative 1. This is critical because:

• Positive antibodies confirm autoimmune diabetes (Type 1 or LADA)
• Negative antibodies in someone <35 years without type 2 features still suggests type 1 (5-10% of type 1 patients are antibody-negative)

Step 3: Consider MODY Testing If:

• A1C <7.5% at diagnosis
• One parent with diabetes
• Specific features: renal cysts, partial lipodystrophy, maternally inherited deafness
• MODY calculator probability >5% 1

Treatment Implications

Your C-peptide level of 0.94 ng/mL indicates significant beta-cell dysfunction and likely insulin requirement. Recent research demonstrates that C-peptide values below 0.95 ng/mL effectively differentiate type 1 from type 2 diabetes with 82% sensitivity and 77% specificity 2. Additionally, values below 1.09 ng/mL predict the need for basal-bolus insulin therapy rather than basal insulin alone 3.

Practical Management Decisions:

If antibody-positive or clinical features suggest Type 1/LADA:

• Initiate insulin therapy immediately
• Consider basal-bolus regimen given the low C-peptide
• Do not attempt oral agent monotherapy

If antibody-negative with Type 2 features:

• Trial of non-insulin therapy may be appropriate, but monitor closely 1
• SGLT-2 inhibitors preferred over insulin secretagogues to preserve remaining beta-cell function 4
• Low threshold to initiate insulin given borderline C-peptide

Critical Caveats

Testing Conditions Matter:

The 2025 ADA guidelines emphasize that C-peptide interpretation requires proper testing conditions 1:

• Must be measured when concurrent glucose is >70 mg/dL (>4 mmol/L)
• If fasting or glucose <70 mg/dL, repeat the test
• Do not test within 2 weeks of hyperglycemic emergency
• For insurance purposes (pump coverage), measure when fasting glucose ≤220 mg/dL 5

Assay Standardization Issues:

A major limitation is the lack of C-peptide assay standardization 6. Different manufacturers show significant variability in results, which can affect classification decisions. The ADA/EASD cut-offs (<0.2 nmol/L for type 1, >0.6 nmol/L for type 2) assume standardized measurements that don't yet exist in practice 6.

Prognostic Significance

Beyond classification, your C-peptide level has prognostic implications:

• Predicts treatment response: Low C-peptide indicates poor response to oral agents and need for insulin 7, 4
• Correlates with disease duration: C-peptide shows inverse correlation with diabetes duration (r = -0.24, p = 0.03) 3
• Guides therapy intensification: Values in this range typically require basal-bolus insulin rather than basal-only regimens 3

Bottom Line for Clinical Action

With a C-peptide of 0.94 ng/mL, you should:

1. Order GAD antibodies immediately (then IA-2/ZnT8 if negative)
2. Assess for clinical features of type 1 vs type 2 diabetes systematically
3. Plan for insulin therapy as this level indicates insufficient beta-cell reserve for oral agents alone in most cases
4. Consider MODY testing if family history and clinical features suggest it
5. Avoid insulin secretagogues if attempting oral therapy, as they may accelerate beta-cell failure 4

The measurement confirms significant beta-cell dysfunction requiring aggressive management, regardless of final diabetes subtype classification 5, 8.